CN107513065B - 一种恩替卡韦中间体iv制备方法 - Google Patents
一种恩替卡韦中间体iv制备方法 Download PDFInfo
- Publication number
- CN107513065B CN107513065B CN201710657770.7A CN201710657770A CN107513065B CN 107513065 B CN107513065 B CN 107513065B CN 201710657770 A CN201710657770 A CN 201710657770A CN 107513065 B CN107513065 B CN 107513065B
- Authority
- CN
- China
- Prior art keywords
- entecavir intermediate
- entecavir
- preparation
- reaction
- phase transfer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- SYPCZZWUNIHLBU-UHFFFAOYSA-N 5-(2-amino-6-phenylmethoxypurin-9-yl)-3-phenylmethoxy-2-(phenylmethoxymethyl)cyclopentan-1-ol Chemical compound C=12N=CN(C3C(C(COCC=4C=CC=CC=4)C(OCC=4C=CC=CC=4)C3)O)C2=NC(N)=NC=1OCC1=CC=CC=C1 SYPCZZWUNIHLBU-UHFFFAOYSA-N 0.000 title claims abstract description 11
- 238000002360 preparation method Methods 0.000 title claims description 7
- 239000003444 phase transfer catalyst Substances 0.000 claims abstract description 7
- 239000007788 liquid Substances 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims abstract description 5
- 239000002904 solvent Substances 0.000 claims abstract description 5
- 229960000980 entecavir Drugs 0.000 claims abstract description 4
- YXPVEXCTPGULBZ-WQYNNSOESA-N entecavir hydrate Chemical compound O.C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)C1=C YXPVEXCTPGULBZ-WQYNNSOESA-N 0.000 claims abstract description 4
- XWNJMSJGJFSGRY-UHFFFAOYSA-N 2-(benzylamino)-3,7-dihydropurin-6-one Chemical compound N1C=2N=CNC=2C(=O)N=C1NCC1=CC=CC=C1 XWNJMSJGJFSGRY-UHFFFAOYSA-N 0.000 claims abstract description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 11
- 238000006243 chemical reaction Methods 0.000 claims description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- HTZCNXWZYVXIMZ-UHFFFAOYSA-M benzyl(triethyl)azanium;chloride Chemical compound [Cl-].CC[N+](CC)(CC)CC1=CC=CC=C1 HTZCNXWZYVXIMZ-UHFFFAOYSA-M 0.000 claims description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 4
- 239000003513 alkali Substances 0.000 claims description 3
- 229940068918 polyethylene glycol 400 Drugs 0.000 claims description 3
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 claims description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims 3
- 229910000103 lithium hydride Inorganic materials 0.000 abstract description 6
- 230000015572 biosynthetic process Effects 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 238000003786 synthesis reaction Methods 0.000 abstract description 4
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 abstract 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Natural products CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 14
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 239000000203 mixture Substances 0.000 description 8
- 239000007787 solid Substances 0.000 description 6
- SIAPCJWMELPYOE-UHFFFAOYSA-N lithium hydride Chemical compound [LiH] SIAPCJWMELPYOE-UHFFFAOYSA-N 0.000 description 5
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 239000002585 base Substances 0.000 description 2
- SYPCZZWUNIHLBU-COROXYKFSA-N (1s,2s,3s,5s)-5-(2-amino-6-phenylmethoxypurin-9-yl)-3-phenylmethoxy-2-(phenylmethoxymethyl)cyclopentan-1-ol Chemical compound C=12N=CN([C@@H]3[C@H]([C@H](COCC=4C=CC=CC=4)[C@@H](OCC=4C=CC=CC=4)C3)O)C2=NC(N)=NC=1OCC1=CC=CC=C1 SYPCZZWUNIHLBU-COROXYKFSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710657770.7A CN107513065B (zh) | 2017-08-03 | 2017-08-03 | 一种恩替卡韦中间体iv制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710657770.7A CN107513065B (zh) | 2017-08-03 | 2017-08-03 | 一种恩替卡韦中间体iv制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107513065A CN107513065A (zh) | 2017-12-26 |
CN107513065B true CN107513065B (zh) | 2021-06-22 |
Family
ID=60722389
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710657770.7A Active CN107513065B (zh) | 2017-08-03 | 2017-08-03 | 一种恩替卡韦中间体iv制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107513065B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113004281A (zh) * | 2019-12-21 | 2021-06-22 | 南通诺泰生物医药技术有限公司 | 一种恩替卡韦中间体的制备方法 |
CN111362943A (zh) * | 2020-03-17 | 2020-07-03 | 南京康立瑞生物科技有限公司 | 一种恩替卡韦中间体n4的制备方法 |
CN115650983A (zh) * | 2022-10-27 | 2023-01-31 | 南京康立瑞生物科技有限公司 | 一种恩替卡韦中间体n4的合成方法 |
CN115850280A (zh) * | 2022-12-08 | 2023-03-28 | 南京康立瑞生物科技有限公司 | 一种抗病毒药恩替卡韦中间体n4的制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102477036A (zh) * | 2010-11-23 | 2012-05-30 | 上海永鸿实业集团化学科技有限公司 | 一种制备恩替卡韦一水合物的方法 |
KR20120091971A (ko) * | 2010-12-23 | 2012-08-20 | (주) 성운파마코피아 | 엔테카비어 제조방법 |
CN102952135A (zh) * | 2011-08-31 | 2013-03-06 | 南京工业大学 | 一种乙肝药物恩替卡韦的合成方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7511139B2 (en) * | 2004-06-04 | 2009-03-31 | Bristol-Myers Squibb Company | Process for the preparation of entecavir and novel intermediates thereof via carbon-silicon oxidation |
-
2017
- 2017-08-03 CN CN201710657770.7A patent/CN107513065B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102477036A (zh) * | 2010-11-23 | 2012-05-30 | 上海永鸿实业集团化学科技有限公司 | 一种制备恩替卡韦一水合物的方法 |
KR20120091971A (ko) * | 2010-12-23 | 2012-08-20 | (주) 성운파마코피아 | 엔테카비어 제조방법 |
CN102952135A (zh) * | 2011-08-31 | 2013-03-06 | 南京工业大学 | 一种乙肝药物恩替卡韦的合成方法 |
Non-Patent Citations (1)
Title |
---|
Synthesis and Antiviral Evaluation of G"-Substituted Aristeromycins: Potential Mechanism-Based Inhibitors of S -Adenosylhomocysteine Hydrolase;G. V. Bindu Madhavan et al.;《J. Med. Chem.》;19881231;第31卷;417-419 * |
Also Published As
Publication number | Publication date |
---|---|
CN107513065A (zh) | 2017-12-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107513065B (zh) | 一种恩替卡韦中间体iv制备方法 | |
CN101456855B (zh) | 1,3-丙磺酸内酯的制备方法 | |
CN104045602A (zh) | 一种缬沙坦成四氮唑的改进方法 | |
CN110590706B (zh) | 一种n-甲基吡咯烷的制备方法 | |
CN103232333B (zh) | 一种环丙乙炔重要中间体环丙基甲基酮的制备方法 | |
CN109956884B (zh) | 一种苄氧胺盐酸盐的制备方法 | |
CN103739545B (zh) | 一种简便的维生素b6的制备方法 | |
CN103772278A (zh) | 一种重要四氢异喹啉衍生物中间体及其合成方法 | |
CN104961787B (zh) | 一种虫草素的合成方法 | |
CN108623602B (zh) | 一种制备和纯化依鲁替尼的方法 | |
CN111018838A (zh) | 吡咯烷基二氨基嘧啶氮氧化物的合成方法 | |
CN103275056B (zh) | 一种替卡格雷中间体的制备方法 | |
CN105017044A (zh) | 一种反式-4-氨甲基环己基甲酸的制备方法 | |
CN102674253A (zh) | 一种氢碘酸的制备方法 | |
CN102718654A (zh) | 一种a-环戊基扁桃酸甲酯的制备方法 | |
CN102432594B (zh) | 一种药物中间体1-(3-羟甲基吡啶-2-基)-2-苯基-4-甲基哌嗪的制备方法 | |
CN109438307A (zh) | 一种l-硒代蛋氨酸的制备方法 | |
CN103980229A (zh) | 一种n-苯基哌嗪的制备方法 | |
CN111138269B (zh) | 一种制备2-丁酮酸钠盐的工艺方法 | |
CN101463033B (zh) | 一种二羟丙茶碱的合成方法 | |
CN103641676A (zh) | 一种制备甲基环戊二烯的方法 | |
CN107216332A (zh) | 叔丁基‑7‑羟甲基‑7,8‑二氢4h吡唑并二氮杂卓5(6h)甲酸基酯的合成方法 | |
CN106749087B (zh) | (e/z)-2-(2-氨基噻唑-4-基)-2-戊烯酸甲酯废液的回收处理工艺 | |
CN103183592B (zh) | 2-氯-1,1,1-三烷氧基乙烷的制备方法 | |
CN111004184A (zh) | 一种4,6-二氯嘧啶的合成工艺 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Li Long Inventor after: Wu Hucheng Inventor after: Dai Liming Inventor after: Cao Junjie Inventor after: Huang Huazi Inventor after: Zhang Ming Inventor after: Dong Daomin Inventor before: Dong Daomin |
|
CB03 | Change of inventor or designer information | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A method for preparing intermediate IV of entecavir Granted publication date: 20210622 Pledgee: Zhejiang Shaoxing Ruifeng Rural Commercial Bank Co.,Ltd. Binhai sub branch Pledgor: ZHEJIANG WARRANT PHARMACEUTICAL CO.,LTD. Registration number: Y2024980003991 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |